Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
CureWise is an AI Cancer Navigator for cancer patients. It aims to bring scattered medical records, complex medical terminology, treatment options, and clinical trial information into one platform that patients can understand and take to appointments for discussion. It is explicitly positioned as an educational and informational tool: it does not provide medical advice, diagnosis, or treatment recommendations, and it is not a substitute for an oncologist.
The platform is built around three stages: “Understand, Discover, Advocate.” First, it can connect to thousands of healthcare institutions in the United States and import materials such as lab results, doctors’ notes, and imaging reports to create a continuously updated clinical summary. AI agents then translate diagnoses, test results, and treatment options into plain language, explaining them at the level of detail the patient prefers.
Beyond that, CureWise combines the latest research, clinical trials, and emerging therapies to explore personalized treatment directions based on cancer type, stage, molecular characteristics, and treatment history. It also provides comparisons between options, supporting evidence, and questions to bring to medical appointments. Clinical trial matching is another key focus: the site says it can search more than 15,000 active oncology trials worldwide and explain why a trial may be relevant, along with eligibility factors.
The product is currently in early access. Eligible applicants can use it free for 3 months, including the full platform, multi-agent analysis, clinical trial matching, medication management, symptom and activity tracking, and email support. After that, monthly billing is 50 USD/month, while annual billing is 499 USD/year. These are still preliminary prices and may change.
Its main strength is a very focused use case: it covers the full workflow from understanding one’s condition to preparing for consultations, making it especially relevant for cancer patients with complex records, uncertain treatment paths, or an active interest in clinical trials. It also emphasizes that patients can control what they share and revoke access, and it sets out medical disclaimers in a relatively cautious way.
The limitations are that the site does not disclose the specific models used, the sources of its medical knowledge base, accuracy metrics, clinical validation, or any human review process. Privacy and compliance details are also insufficient: HIPAA, encryption, data retention, and whether data is used for model training are not explained. There is likewise no information on Chinese-language support, API availability, or payment methods.
CureWise is better suited to patients receiving care within the U.S. healthcare system who need to consolidate records from multiple institutions and prepare for in-depth discussions with oncologists. Chinese users may face issues with medical record connectivity, an English-language interface, and cross-border medical data compliance. Network accessibility and payment availability in mainland China have not been disclosed, so they are currently rated as unknown. If used in China, it should be treated as a reference tool for organizing information, not as a basis for treatment decisions.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on curewise.com official site.
curewise.com is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach curewise.com directly.